Recent public signals classified as FDA Approval, with first-party permanent pages for source and price-impact review.
Protagonist Therapeutics announced Takeda's FDA approval of MIMRYLO (rusfertide) for polycythemia vera, triggering $275 million in payments and up to $875 million more in milestones, plus 14–29% royalties. The milestone-rich deal reinforces PTGX’s revenue potential and validates its peptide platform, following a second FDA approval in 2026. Commercial uptake by Takeda will largely drive near-term value realization for PTGX.
View signal analysis →LLY announced FDA approval of Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high risk. SURPASS-CVOT results showed non-inferiority to dulaglutide with an 8% MACE-3 advantage across 13,299 participants over a median ~210 weeks. The label expansion could broaden Mounjaro's addressable market and lift near-term revenue.
View signal analysis →Pfizer and BioNTech won FDA approval for the 2026-27 COMIRNATY XFG vaccine, enabling immediate U.S. shipping. The sBLA is supported by safety, efficacy, and cross-variant data, with use in adults 65+ and 5-64 with high-risk conditions. This regulatory milestone could lift near-term vaccine revenue and position the partners for the fall vaccination season.
View signal analysis →Adicet Bio announced FDA cleared IND for ADI-212 targeting PSMA in metastatic castration-resistant prostate cancer, with Phase 1 enrollment expected in Q4 2026. The off-the-shelf, gene-edited armored CAR T therapy aims to enhance potency in solid tumors, potentially broadening Adicet's platform beyond hematologic malignancies. The milestone could lift sentiment ahead of readouts and future trial data.
View signal analysis →Moderna's updated Spikevax and mNEXSPIKE vaccines targeting the JN.1 XFG subvariant received FDA approval, expanding eligibility for high-risk populations and older adults. Availability is expected in coming days, with prior regulatory clearances in Europe and Asia reinforcing the rollout. The development could bolster near-term vaccine sales and strengthen Moderna's position ahead of the upcoming respiratory season.
View signal analysis →The FDA De Novo authorization of Libre Duo 10 Day marks Abbott's first dual glucose-ketone sensing system, expanding its diabetes-care platform. With US launch planned later this year and anticipated integrations with major automated insulin delivery systems, the move could lift ABT's long-term addressable market and revenue in 2026-2027.
View signal analysis →